Andrew Boll Buys 3,500 Shares of Harrow (NASDAQ:HROW) Stock

Harrow, Inc. (NASDAQ:HROW) CFO Andrew Boll purchased 3,500 shares of Harrow stock in a transaction dated Thursday, May 14th. The stock was bought at an average price of $29.90 per share, for a total transaction of $104,650.00. Following the completion of the transaction, the chief financial officer directly owned 814,679 shares in the company, valued at $24,358,902.10. The trade was a 0.43% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Harrow Stock Up 1.1%

NASDAQ:HROW opened at $31.21 on Friday. Harrow, Inc. has a 12-month low of $25.21 and a 12-month high of $54.85. The company has a quick ratio of 2.06, a current ratio of 2.48 and a debt-to-equity ratio of 10.30. The firm has a market capitalization of $1.16 billion, a P/E ratio of -76.12 and a beta of 0.34. The stock’s fifty day simple moving average is $36.51 and its 200-day simple moving average is $42.13.

Harrow (NASDAQ:HROW) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.31). Harrow had a positive return on equity of 19.59% and a negative net margin of 5.57%.The company had revenue of $44.20 million during the quarter, compared to the consensus estimate of $52.43 million. During the same quarter in the prior year, the business earned ($0.38) earnings per share. Equities research analysts expect that Harrow, Inc. will post 0.37 earnings per share for the current year.

Institutional Trading of Harrow

Hedge funds have recently added to or reduced their stakes in the business. University of Texas Texas AM Investment Management Co. acquired a new stake in Harrow during the 4th quarter worth $26,000. KBC Group NV acquired a new stake in Harrow during the 1st quarter worth $31,000. Raymond James Financial Inc. acquired a new stake in shares of Harrow in the 2nd quarter valued at about $48,000. SBI Securities Co. Ltd. raised its stake in shares of Harrow by 393.5% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,061 shares of the company’s stock valued at $52,000 after purchasing an additional 846 shares during the period. Finally, State of Alaska Department of Revenue acquired a new stake in shares of Harrow in the 3rd quarter valued at about $83,000. Institutional investors and hedge funds own 72.76% of the company’s stock.

Analyst Ratings Changes

HROW has been the topic of several recent research reports. HC Wainwright restated a “buy” rating and issued a $70.00 price target on shares of Harrow in a research report on Thursday, March 19th. Weiss Ratings downgraded Harrow from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, April 22nd. Nomura downgraded Harrow to a “neutral” rating in a research note on Wednesday, March 18th. B. Riley Financial reaffirmed a “buy” rating and set a $65.00 price objective (down from $74.00) on shares of Harrow in a research note on Tuesday, April 7th. Finally, Cantor Fitzgerald dropped their price objective on Harrow from $91.00 to $88.00 and set an “overweight” rating on the stock in a research note on Wednesday. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $69.43.

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.